Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov-Dec;25(11-12):515-21.
doi: 10.1007/s10815-008-9266-6. Epub 2008 Oct 30.

Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

Dharmawijaya N Lekamge  1 , Michelle Lane, Robert B Gilchrist, Kelton P Tremellen
Affiliations

Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

Dharmawijaya N Lekamge et al. J Assist Reprod Genet. 2008 Nov-Dec.

Abstract

Purpose: This retrospective study was carried out to evaluate whether increasing the starting dose of FSH stimulation above the standard dose of 150 IU/day in patients with low predicted ovarian reserve can improve IVF outcomes.

Method: A total of 122 women aged less than 36 years in their first cycle of IVF were identified as having likely low ovarian reserve based on a serum AMH measurement below 14 pmol/l. Thirty five women were administered the standard dose of 150 IU/day FSH, while the remaining 87 received a higher starting dose (200-300 IU/day FSH). There were no significant differences in age, BMI, antral follicle count, serum AMH, FSH or aetiology of infertility between the two dose groups.

Results: No significant improvement in oocyte and embryo yield or pregnancy rates was observed following an upward adjustment of FSH starting dose. While increasing the dose of FSH above 150 IU/day did not produce any adverse events such as OHSS, it did consume an extra 1,100 IU of FSH per IVF cycle.

Conclusion: The upward FSH dose adjustment in anticipation of low ovarian reserve can not be advocated as it is both expensive and of no proven clinical value.

PubMed Disclaimer

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0015-0282(99)00334-9', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0015-0282(99)00334-9'}, {'type': 'PubMed', 'value': '10521109', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10521109/'}]}
    2. De Vries MJ, De Sutter P, Dhont M. Prognostic factors in patients continuing in vitro fertilization or intracytoplasmic sperm injection treatment and dropouts. Fertil Steril. 1999;72:674–8. doi:10.1016/S0015-0282(99)00334-9. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0015-0282(02)03160-6', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0015-0282(02)03160-6'}, {'type': 'PubMed', 'value': '12095488', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12095488/'}]}
    2. Sharma V, Allgar V, Rajkhowa M. Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility. Fertil Steril. 2002;78:40–6. doi:10.1016/S0015-0282(02)03160-6. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1093/humrep/deg472', 'is_inner': False, 'url': 'https://doi.org/10.1093/humrep/deg472'}, {'type': 'PubMed', 'value': '14585873', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14585873/'}]}
    2. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment. Hum Reprod. 2003;18:2275–82. doi:10.1093/humrep/deg472. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '2106451', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/2106451/'}]}
    2. Pantos C, Thornton SJ, Speirs AL, Johnston I. Increasing the human menopausal gonadotropin dose—does the response really improve? Fertil Steril 1990;53:436–9. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1093/humrep/deg181', 'is_inner': False, 'url': 'https://doi.org/10.1093/humrep/deg181'}, {'type': 'PubMed', 'value': '12660271', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12660271/'}]}
    2. Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003;18:781–7. doi:10.1093/humrep/deg181. - PubMed

Publication types

Substances

LinkOut - more resources